U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Fallntolol is a beta-adrenergic receptor antagonist. Falintolol does not produce any noteworthy side effects and is capable of being an effective beta-blocking agent in open-angle glaucoma therapy.

Originator

Curator's Comment: reference retrieved from https://link.springer.com/chapter/10.1007/978-1-4757-2085-3_6

Approval Year

PubMed

PubMed

TitleDatePubMed
Pharmacokinetics of falintolol II. Absorption, distribution and elimination from tissues and organs following ocular administration and intravenous injection of falintolol in albino rabbits.
1989-12
Determination of falintolol, a new aliphatic beta-adrenergic antagonist, in whole blood by gas chromatography with electron-capture detection: geometric isomers resolution.
1987-01
Effects of topically applied falintolol: a new beta-adrenergic antagonist for treatment of glaucoma.
1987
New chiral and isomeric cyclopropyl ketoxime propanolamine derivatives with potent beta-adrenergic blocking properties.
1985-07
In vitro potential measurement, anaesthetic and antimicrobial effects as indicators of beta-blocker toxicity of the cornea.
1985-04
Synthesis and beta-adrenergic blocking activity of new aliphatic and alicyclic oxime ethers.
1984-10
Name Type Language
FALINTOLOL OXALATE, (±)-
Preferred Name English
FALINTOLOL OXALATE
Common Name English
ETHANONE, 1-CYCLOPROPYL-, O-(3-((1,1-DIMETHYLETHYL)AMINO)-2-HYDROXYPROPYL)OXIME, ETHANEDIOATE (1:1) (SALT)
Systematic Name English
Code System Code Type Description
FDA UNII
8ZG1XG255D
Created by admin on Wed Apr 02 15:54:47 GMT 2025 , Edited by admin on Wed Apr 02 15:54:47 GMT 2025
PRIMARY
CAS
99051-41-9
Created by admin on Wed Apr 02 15:54:47 GMT 2025 , Edited by admin on Wed Apr 02 15:54:47 GMT 2025
ALTERNATIVE
CAS
88134-93-4
Created by admin on Wed Apr 02 15:54:47 GMT 2025 , Edited by admin on Wed Apr 02 15:54:47 GMT 2025
PRIMARY
All of the following components must be present:
Definition References